Browse by Medical Category
Not Accepting New Patients
Dr. Papaliodis is board certified in Internal Medicine and Ophthalmology. He is an Internal Medicine hospitalist and the director of the Uveitis and Immunology Service in the Department of Ophthalmology. His MEEI offices are in Boston and Stoneham.
Go To Programs
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Board-certified in internal medicine and ophthalmology, Dr. George Papaliodis specializes in the treatment of systemic diseases that are associated with ocular inflammation. As the director of the Ocular Immunology and Uveitis Service, he treats patients with a range of ocular inflammatory disorders at Mass. Eye and Ear's main Charles Street campus and Stoneham satellite office, as well at Massachusetts General Hospital. In addition, as a member of the Comprehensive Ophthalmology and Cataract Consultation Service, he performs cataract surgery at Mass. Eye and Ear's Charles Street location.
Dr. Papaliodis earned his medical degree and completed an ophthalmology residency at the University of Texas Southwestern School of Medicine. He went on to complete an additional residency in Internal Medicine at Harvard Medical School/Massachusetts General Hospital, followed by subspecialty training in ocular immunology and uveitis at Mass. Eye and Ear.
A renowned expert in ocular inflammatory diseases, Dr. Papaliodis has presented at many national and international conferences, including those hosted by the International Ocular Inflammation Society, the American College of Rheumatology, the Aegean Retina Society, the New England Ophthalmologic Society, the North Carolina Dermatology Society, the Dominican Republic National Ophthalmologic Society, the Association for Research in Vision and Ophthalmology, and SECO International.
Board-certified in internal medicine and ophthalmology, Dr. Papaliodis specializes in the treatment of systemic diseases that induce ocular inflammation. He has been involved in a multiple research projects attempting to identify disease mechanisms and novel treatments for uveitis, including an investigation of LX-211 for the treatment of ocular inflammatory diseases and pulsed electromagnetic field therapy for the treatment of uveitis. He also studied serum biomarkers and genetics in ocular sarcoidosis and was an investigator in the Abbvie sponsored study obtaining FDA approval for Humira for the treatment of uveitis. In addition to establishing one of the largest ocular inflammatory disease practices in the country, he has personally outlined the teaching curriculum in the field of uveitis/ocular inflammation for the residents at Harvard Medical School.
View my most recent publications at PubMed
Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis. William M, Faez S, Papaliodis GN, Lobo AM. J Ophthalmic Inflamm Infect. 2012 Dec;2(4):231-3.
Treatment of seronegative spondyloarthropathy-associated uveitis with golimumab: retrospective case series. Faez S, Lobo AM, Sobrin L, Papaliodis GN. Clin Experiment Ophthalmol. 2014 May-Jun;42(4):392-5.
Role of OCT in the diagnosis and management of macular edema from uveitis. Hunter RS, Skondra D, Papaliodis G, Sobrin L. Semin Ophthalmol. 2012 Sep-Nov;27(5-6):236-41.
Eales' Disease. Papaliodis GN. [Online publication, Uptodate.com]. 2011-present
Paraneoplastic conjunctival cicatrization: two different pathogenic types. Ahuero AE, Jakobiec FA, Bhat P, Ciralsky JB, Papaliodis GN. Ophthalmology. 2010 Apr;117(4):659-64.
Back to Top